<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03594448</url>
  </required_header>
  <id_info>
    <org_study_id>3C-18-2</org_study_id>
    <secondary_id>NCI-2018-01169</secondary_id>
    <secondary_id>3C-18-2</secondary_id>
    <secondary_id>P30CA014089</secondary_id>
    <nct_id>NCT03594448</nct_id>
  </id_info>
  <brief_title>Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients</brief_title>
  <official_title>Detection of Microsatellite Instability (MSI) in Circulating Tumor DNA of Patients With Stage IV Colorectal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot trial studies how well serial liquid biopsies work in detecting microsatellite
      instability in participants with stage IV colorectal cancer. Serial liquid biopsies may help
      doctors learn better methods to track cancer in the bloodstream and how to use these to
      improve cancer treatments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To test the hypothesis that there is high level of concordance between the electrophoretic
      mobility profile of microsatellite biomarkers in circulating cell-free deoxyribonucleic acid
      (ccfDNA) versus in primary tumor tissues in patients with colorectal carcinomas displaying
      microsatellite instability.

      II. To test the hypothesis that changes in the electrophoretic mobility profile of
      microsatellite biomarkers in liquid biopsies from patients with colorectal carcinoma
      correlate with therapeutic responsiveness measured based on Response Evaluation Criteria in
      Solid Tumors (RECIST) criteria.

      III. To determine whether microsatellite alleles generated as a result of microsatellite
      instability detectable in liquid biopsy specimens from patients with colorectal carcinoma
      represent the entire cancer cell population or only a subset of cancer cells differentially
      affected by genomic instability.

      OUTLINE:

      Participants undergo collection of blood samples to evaluate microsatellite instability via
      serial liquid biopsies at baseline, then every 6 weeks and at progression or 9 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 5, 2018</start_date>
  <completion_date type="Anticipated">September 5, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 5, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between presence of MSI present in circulating tumor DNA versus in primary tumor specimens</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>MSI testing distinguishes between tumors into one of 3 phenotypic categories: MSI-High (MSI-H) is reported when &gt; 30% of biomarkers show instability; Microsatellite stable (MSS) is reported in the absence of instability. The third category, MSI-Low (MSI-L) is diagnostically equivalent to MSS, and is reported when MSI is present in &lt; 30% of biomarkers. MSI status will be determined by polymerase chain reaction (PCR) using commercial kits provided by Promega.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Microsatellite Instability</condition>
  <condition>Colorectal Cancer Stage IV</condition>
  <arm_group>
    <arm_group_label>Ancillary-correlative (Specimen collection)</arm_group_label>
    <description>Participants undergo collection of blood samples in addition to the usual amount collected when they come in for their regular cancer treatments or doctor?s appointment every 6-8 weeks until disease progression or stopping at 9 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Specimen Collection</intervention_name>
    <description>Undergo collection of blood samples</description>
    <arm_group_label>Ancillary-correlative (Specimen collection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Serial Liquid Biopsy</intervention_name>
    <description>Undergo serial liquid biopsy</description>
    <arm_group_label>Ancillary-correlative (Specimen collection)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients newly diagnosed with stage IV colorectal cancer and with defined microsatellite
        instability status before initiation of systemic immunotherapy will be recruited.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients newly diagnosed with stage IV colorectal cancer and with defined
             microsatellite instability status before initiation of systemic immunotherapy.

          -  Trackable cancer-driver mutation in the primary tumor documented before initiation of
             chemotherapy.

          -  Zubrod performance status of 0 or 1.

          -  Patients have measurable disease according to RECIST version (v)1.1.

          -  Ability to understand and willing to sign a written informed consent.

        Exclusion Criteria:

          -  Severe anemia (hemoglobin [Hb] &lt; 8 g/dL).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Afsaneh Barzi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dana Agafitei</last_name>
    <phone>323-865-0467</phone>
    <email>Raluca.Agafitei@med.usc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rabia Rehman</last_name>
    <phone>323‐865‐0460</phone>
    <email>Rabia.Rehman@med.usc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Afsaneh Barzi</last_name>
      <phone>323-865-3829</phone>
      <email>afsaneh.barzi@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Afsaneh Barzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana L. Hanna</last_name>
      <phone>949-764-6130</phone>
      <email>Diana.Hanna@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Diana L. Hanna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC Norris Oncology/Hematology‐Newport Beach</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristy Massopust</last_name>
      <phone>949‐474‐5733</phone>
      <email>Kristy.Massopust@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Umair Ghani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 11, 2018</study_first_submitted>
  <study_first_submitted_qc>July 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2018</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Microsatellite Instability</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

